Catalys Pacific is an independent venture capital firm based in Tokyo that creates and invests in early-stage life sciences and biotech companies through a transpacific company-creation model linking Japan and the United States.
46% of their portfolio is in Biotech & Life Sciences. Deal activity increased 300% year-over-year (4 deals in the last 12 months). Average disclosed round size is $106.7M (across 20 rounds with reported amounts).
Portfolio
14
Fund Size
—
Top Stage
Series A
Last 12 Mo
4
Team
BT Slingsby, MD, PHD, MPH
Founder & Managing Director
Takeshi Takahashi, MBA
Managing Director
Jon Congleton
Operating Partner
Mitsuyuki “Mickey” Matsumoto, PhD
Operating Partner
Neal Fowler, MBA
Operating Partner
Ryutaro Shimazaki
Operating Partner
Sandy Mong, MD
Partner
Seth H Z Fischer
Venture Partner
Jogen Atone
Principal
Hayato Urabe, PhD, MPIA
Vice President
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Crystalys | Series A | $205M | Sep 2026 |
 Crystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
| Crystalys | Series A | $205M | Sep 2025 |
| Crystalys Therapeutics Inc | Series A | $205M | Sep 2025 |
| AAculys Pharma, Inc. | Series C | — | Mar 2025 |
| AAculys Pharma, Inc. | Series C | — | Jan 2025 |
 Pathalys | Series B | $105M | Aug 2024 |
| PPathalys Pharma | Series B | $105M | Aug 2024 |
| AArialys Therapeutics | Seed | $58M | Sep 2023 |
| Pathalys | Growth | $150M | Jan 2023 |
| MMineralys | Series B | $118M | Jun 2022 |
| MMineralys | Series B | $118M | Jan 2022 |
| MMineralys Therapeutics, Inc. | Series B | $118M | Jan 2022 |
 HilleVax | Unknown | $135M | Sep 2021 |
 Mineralys Therapeutics | Series A | $40M | Apr 2021 |
| MMineralys | Series A | $40M | Apr 2021 |
| MMineralys Therapeutics, Inc. | Series A | $40M | Apr 2021 |
| MMineralys Therapeutics, Inc. | Series A | $40M | Jan 2021 |
 Mineralys Therapeutics | Series A | — | Jan 2021 |
 Exalys Therapeutics Inc. | Series A | $15M | Jul 2020 |
 Aculys | Series C | — | — |
 Arialys | Seed | $58M | — |
| Mineralys Therapeutics | Series B | $118M | — |
| Crystalys | Series B | $130M | — |
Top Co-Investors
Last updated: 20 October 2026